Lastly, concurrent inhibition of the KRAS pathway with sotorasib and batoprotafib demonstrated combination activity in spheroids containing KRAS G12C.<h4>Significance</h4>KRAS variants are oncogenic drivers for a range of human cancers. Here, KRAS is linked to cancer.